Advertisement

Topics

Discovery Laboratories Company Profile

12:37 EDT 20th September 2017 | BioPortfolio

Discovery Laboratories, Inc. is a specialty pharmaceutical company leveraging its platform technology in humanized lung surfactants to develop novel respiratory therapies and pulmonary drug delivery products. Surfactants are produced naturally in the lungs and are essential to the lungs' ability to absorb oxygen.

Our humanized surfactant technology is being developed initially for critical care patients with life-threatening respiratory disorders where there are few or no approved therapies available. Surfaxin®, our lead product, is currently in Phase 3 clinical trials for Respiratory Distress Syndrome in premature infants (RDS), a Phase 3 clinical trial for Meconium Aspiration Syndrome in full-term infants (MAS), and a Phase 2 clinical trial for Acute Lung Injury/Acute Respiratory Distress Syndrome in adults (ALI/ARDS).



We are also developing aerosolized formulations of our humanized surfactant to treat respiratory conditions such as asthma and as a novel pulmonary drug delivery vehicle to render drugs more effective when delivered to or via the respiratory tract.



A lack of functional surfactant is associated with several severe respiratory diseases. Research has established that surfactant replacement is highly effective in treating RDS and holds great promise in treating MAS, ALI/ARDS, asthma and other respiratory disorders. However, RDS is the only respiratory disease being treated today with approved surfactants, which are principally animal derived. The current supply of these surfactants is limited and their manufacture is both inexact and expensive, making it difficult to develop these products to treat broader populations for RDS therapy or other respiratory diseases.



Because our products are based on an engineered humanized surfactant, they can be produced economically at scale, as a high quality pharmaceutical, without the risk of potential transmission of animal-borne diseases or adverse immunological reaction. Products from our technology platform have the potential to be superior to currently marketed surfactants, treat critical care respiratory conditions, and treat larger, ambulatory patient populations that could benefit from surfactant therapy or drug delivery.

Location

2600 Kelly Road, Suite 100
Warrington
PA
18976-3622
United States of America

Contact

Phone: 215.488.9300
Fax: 215.488.9301
Email: ir@discoverylabs.com


News Articles [859 Associated News Articles listed on BioPortfolio]

Eisai, Charles River Laboratories extend drug discovery partnership

Eisai, a global research and development-based pharmaceutical company, and Charles River Laboratories International, an early-stage CRO, announced an agreement to extend their two-year collaboration ...

£30 Million ‘Discovery' puts Nottingham Firmly on Life Sciences Map

BioCity's new £30 million ‘Discovery Building', providing 50,000 sq ft of high-tech biology and chemistry laboratories, has opened in Nottingham. The building is expected to support m...

Eisai and Charles River Laboratories Announce Extension of Integrated Drug Discovery Partnership

HATFIELD, England and WILMINGTON, Massachusetts, May 30, 2017 /PRNewswire/ -- Companies to continue collaboration in discovery of next generation anti-malaria drugs Eisai Co., Ltd. (TYO: 4523), a ...

Eisai and Charles River Laboratories extend drug discovery collaboration

Eisai and Charles River Laboratories International have agreed to extend their two-year collaboration in integrated drug discovery for another year.

Partnering NSAIDs with Immunotherapy to Fight Cancer

ArticleDrug Discovery & Development spoke to Joseph Murphy, Ph.D., director of science, R&D at Charles River Laboratories about using NSAIDs as an effective anticancer immunotherapy.

Charles River Laboratories updates oncology business

Charles River Laboratories International recently announced updates to its expanding oncology discovery business, including significant additions to its online Tumor Model Compendium. The Compendium p...

Eisai extends CRO partnership for malaria drug discovery

The Japanese drugmaker agreed to add another year to its collaboration in the U.K. with Charles River Laboratories. 

Trash into treasure: Sandia could help biofuel pay for itself with goods made from waste

(DOE/Sandia National Laboratories) A recent discovery by Sandia National Laboratories researchers may unlock the potential of biofuel waste -- and ultimately make biofuels competitive with petroleum. ...

PubMed Articles [872 Associated PubMed Articles listed on BioPortfolio]

Project management: importance for diagnostic laboratories.

The constraints applied on diagnostic laboratories to improve both quality and productivity together with personal shortages incite laboratory managers to constantly optimize the laboratory workflows,...

Role of Academic Drug Discovery in the Quest for New CNS Therapeutics.

There was a greater than 50% decline in central nervous system (CNS) drug discovery and development programs by major pharmaceutical companies from 2009 to 2014. This decline was paralleled by a rise ...

Cancer incidence in female laboratory employees: extended follow-up of a Swedish cohort study.

Work in chemical laboratories is associated with exposure to chemicals, of which some are known or suspected carcinogens. A cohort study of laboratory workers in Stockholm followed until 1992 showed a...

Data-analysis strategies for image-based cell profiling.

Image-based cell profiling is a high-throughput strategy for the quantification of phenotypic differences among a variety of cell populations. It paves the way to studying biological systems on a larg...

Advances in epilepsy gene discovery and implications for epilepsy diagnosis and treatment.

Epilepsy genetics is shifting from the academic pursuit of gene discovery to a clinical discipline based on molecular diagnosis and stratified medicine. We consider the latest developments in epilepsy...

Clinical Trials [365 Associated Clinical Trials listed on BioPortfolio]

Discovery Elbow Multi-Center Prospective Study

The purpose of this prospective clinical trial is to document the performance and clinical outcomes of Biomet Discovery Elbow.

A Clinical Investigation of the Discovery™ Elbow System

The purpose of this study is to perform a five-year, multi-center prospective evaluation of the Discovery™ Elbow System for outcome and durability. Relief of pain and restoration of fun...

A Comparative Clinical Trial to Evaluate the Safety and Clinical Equivalence of Clotrimazole Troche/Lozenges USP, 10mg (Unique Pharmaceutical Laboratories, India) With Clotrimazole Troche 10mg (Roxane Laboratories Inc., USA) in Subjects With Oropharyngeal

The objectives of this study are to compare the efficacy and safety of Clotrimazole troche/ lozenges USP, 10 mg (Unique Pharmaceutical Laboratories, India) vs. Clotrimazole Troche/ Lozenge...

Bioequivalence Study of Meloxicam Tablets 15 mg of Dr.Reddy's Laboratories Limited Under Fed Condition

The objective of this study is to determine the relative bioavailability of one 15 mg Meloxicam tablet (Dr. Reddy. Laboratories Ltd.,Generics) versus one 15 mg Mobic (meloxicam) Tablet (Bo...

Endometriosis Biomarker Discovery Study

This is a prospective, Single time point, discovery study intending to identify biomarkers that can differentiate endometriosis from other underlying reasons for pelvic pain. Patients unde...

Companies [1989 Associated Companies listed on BioPortfolio]

JMI Laboratories

Established in 2000 by Ronald N. Jones, MD, JMI Laboratories serve as microbiology specialists in the development of antimicrobials. Our experienced professionals provide diverse and flexible services...

NCE Discovery Limited

nce discovery was spun out of the Wolfson Institute for Biomedical Research, University College London in 2001 and provides expert medicinal chemistry services to pharmaceutical and biotechnology comp...

Charleston Laboratories, Inc.

Charleston Laboratories Inc, headquartered in Charleston, SC, is a privately funded specialty pharmaceutical company developing and commercializing opioid drugs with minimal or no opioid-induced nause...

ChemBridge Research Laboratories, Inc.

ChemBridge Research Laboratories, Inc. (CRL), http://www.chembridgeresearch.com, is a San Diego based discovery chemistry CRO, which provides chemistry solutions for early stages of small molecule...

KENT LABORATORIES

Since 1974 KENT LABORATORIES has been a specialist in the production of polyclonal antibodies, radial immunodiffusion kits and conjugated immunoglobulin fractions for manufacturers, universities and l...

More Information about "Discovery Laboratories" on BioPortfolio

We have published hundreds of Discovery Laboratories news stories on BioPortfolio along with dozens of Discovery Laboratories Clinical Trials and PubMed Articles about Discovery Laboratories for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Discovery Laboratories Companies in our database. You can also find out about relevant Discovery Laboratories Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Pulmonary
Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza,  Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...

Respiratory
Asthma COPD Cystic Fibrosis Pneumonia Pulmonary Medicine Respiratory Respiratory tract infections (RTIs) are any infection of the sinuses, throat, airways or lungs.  They're usually caused by viruses, but they can also ...


Corporate Database Quicklinks



Searches Linking to this Company Record